Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 989 GBX 0.05% Market Closed
Market Cap: 4.4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Net Income (Common)
$285m
CAGR 3-Years
-15%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
GlaxoSmithKline PLC
LSE:GSK
Net Income (Common)
ÂŁ4B
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
AstraZeneca PLC
LSE:AZN
Net Income (Common)
$6.4B
CAGR 3-Years
20%
CAGR 5-Years
24%
CAGR 10-Years
12%
Verona Pharma PLC
NASDAQ:VRNA
Net Income (Common)
-$153.7m
CAGR 3-Years
-51%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Net Income (Common)
-$141m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Net Income (Common)
-ÂŁ27.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hikma Pharmaceuticals PLC
Glance View

Market Cap
4.4B GBX
Industry
Pharmaceuticals

Hikma Pharmaceuticals PLC, a Jordanian-British multinational, began its journey in the heart of Amman, Jordan, in 1978, founded by Samih Darwazah. Over the years, it has evolved from a local pharmaceutical manufacturer into a global powerhouse, recognized as a key player in the generic pharmaceutical industry. The company's core strategy revolves around the production and distribution of a wide array of generic medications, serving diverse therapeutic categories such as cardiovascular, oncology, and infectious diseases. Hikma's competitive edge lies in its ability to produce high-quality and cost-effective medicines, which are crucial in both high-demand regions and emerging markets where affordable healthcare options are often limited. By leveraging its robust manufacturing capabilities and regulatory expertise, Hikma efficiently supplies generic and branded medications to over 50 countries worldwide, nurturing its growth and bolstering its market position. Driving the gears of Hikma's revenue machine are its three main operational segments: Injectables, Generics, and Branded pharmaceuticals. The Injectables division, a significant contributor to its financial health, supplies hospitals with critical sterile products, benefiting especially when acute care needs surge. Meanwhile, the Generics division continues to expand its footprint in the U.S. market, offering cost-effective alternatives to brand-name drugs, riding the wave of patent expirations. The Branded segment, deeply rooted in the Middle East and North Africa, capitalizes on Hikma's regional expertise and trusted brand reputation. Through this diversified business model, Hikma not only fortifies its financial stability but also ensures resilience against market fluctuations, steering the firm towards sustainable growth amidst an ever-evolving global pharmaceutical landscape.

HIK Intrinsic Value
3 871.5 GBX
Undervaluation 49%
Intrinsic Value
Price

See Also

What is Hikma Pharmaceuticals PLC's Net Income (Common)?
Net Income (Common)
285m USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Net Income (Common) amounts to 285m USD.

What is Hikma Pharmaceuticals PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-1%

Over the last year, the Net Income (Common) growth was 95%. The average annual Net Income (Common) growth rates for Hikma Pharmaceuticals PLC have been -15% over the past three years , -5% over the past five years , and -1% over the past ten years .

Back to Top